10-Q: Ardent Health Partners Reports Q3 2024 Results, Revenue Up 5.2%

Ardent Health Partners saw a 5.2% increase in total revenue for the third quarter of 2024, driven by higher admissions and net patient service revenue.

Summary

• Ardent Health Partners reported a 5.2% increase in total revenue for the three months ended September 30, 2024, reaching $1,449.8 million compared to $1,377.7 million in the same period last year.
• The revenue growth was primarily due to a 3.8% increase in adjusted admissions and a 0.9% increase in net patient service revenue per adjusted admission.
• Admissions grew by 6.4%, while outpatient surgeries saw a modest increase of 0.2%.
• For the nine months ended September 30, 2024, total revenue increased by 7.3% to $4,359.8 million.
• Adjusted admissions for the nine-month period rose by 3.5%, and net patient service revenue per adjusted admission increased by 3.6%.
• The company's net income attributable to Ardent Health Partners, Inc. was $26.3 million for the quarter and $96.1 million for the nine-month period.
• The company completed an initial public offering (IPO) on July 19, 2024, raising net proceeds of approximately $208.6 million.
• A repricing of the Term Loan B Facility was executed on September 18, 2024, reducing the applicable interest rate by 50 basis points.
• The company also amended its ABL Credit Agreement on June 26, 2024, increasing the revolving commitment to $325.0 million and extending its maturity date to June 26, 2029.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and strategic initiatives, but also acknowledges challenges such as the cybersecurity incident and increasing costs. The sentiment is cautiously optimistic.

Positives

• The company experienced strong revenue growth in both the third quarter and the first nine months of 2024.
• The increase in adjusted admissions and net patient service revenue per adjusted admission indicates positive trends in patient volume and pricing.
• The successful completion of the IPO provides the company with additional capital.
• The repricing of the Term Loan B Facility will reduce interest expenses.
• The amendment to the ABL Credit Agreement increases financial flexibility.

Negatives

• Professional fees increased as a percentage of total revenue due to higher costs for hospital-based providers and revenue cycle management services.
• The company incurred a loss on extinguishment and modification of debt of $1.5 million in Q3 2024.
• The company experienced delays in billing claims and obtaining reimbursements and payments through the first quarter of 2024 due to a cybersecurity incident.

Risks

• The company's revenue is subject to potential regulatory and economic changes in certain states where it generates significant revenue.
• The company is exposed to interest rate risk due to its variable rate debt.
• The company continues to incur expenses related to the cybersecurity incident, including legal costs.
• The company faces competition in recruiting and retaining qualified medical personnel.
• The company's operations are subject to complex laws and regulations, and changes in these laws could impact its business.

Future Outlook

The company believes the preliminary estimate of its net benefit under the Oklahoma DPP and the New Mexico HDA Act to be in excess of $150 million on an annualized basis, subject to change, non-recurrence, and adjustment for potential quality performance requirements.

Industry Context

The healthcare industry is experiencing a shift from inpatient to outpatient settings, a growing aged population, and ongoing consolidation of providers and insurers. Ardent's strategic JV model and focus on operational improvements position it to navigate these trends.

Comparison to Industry Standards

• The company's revenue growth of 5.2% in Q3 2024 is a positive sign, indicating a strong demand for its services.
• The increase in adjusted admissions and net patient service revenue per adjusted admission suggests that the company is effectively managing its patient volume and pricing.
• The company's focus on service line optimization and supply chain cost reduction initiatives is in line with industry best practices for improving profitability.
• The company's strategic JV model is a differentiated approach that provides access to expanded networks and clinical talent, which is a competitive advantage.
• The company's efforts to mitigate the impact of the cybersecurity incident and its settlement of the class action lawsuit are important steps in addressing the challenges faced by the healthcare industry.

Legal Proceedings

• The company settled a consolidated class action lawsuit related to the cybersecurity incident, with the settlement requiring cash payments that will not have a material impact on the company's results of operations, financial position, or liquidity.

Related Party Transactions

• The company recorded rent expense related to the Ventas Master Lease and other lease agreements with Ventas for certain medical office buildings of $37.2 million and $36.4 million for the three months ended September 30, 2024 and 2023, respectively, and $111.4 million and $108.9 million for the nine months ended September 30, 2024 and 2023, respectively.
• Ventas beneficially owned approximately 6.5% of the company's outstanding common stock as of September 30, 2024.

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and strategic initiatives.
• Employees may experience changes in compensation and benefits due to cost control measures.
• Customers will continue to receive healthcare services from the company's facilities.
• Suppliers may be affected by the company's supply chain cost reduction initiatives.
• Creditors will be impacted by the company's debt management and financial performance.

Next Steps

• The company will continue to work with its insurance carriers to obtain reimbursement for costs and liabilities related to the cybersecurity incident.
• The company will continue to monitor communications regarding the Texas Waiver Program from the State of Texas and CMS.
• The company will continue to evaluate the impact of recently issued accounting standards on its disclosures.
• The company will continue to implement cost control measures to curb increases in operating costs and expenses.

Key Dates

Keywords

revenue, admissions, healthcare, hospitals, financial results, IPO, debt, cybersecurity, interest rates, EBITDA